

NOF CORPORATION Becomes Shareholder of Phosphorex

Tokyo, Japan – August 9, 2024 – NOF CORPORATION is pleased to announce the completion of a minority investment into Phosphorex, a drug delivery-focused contract development and manufacturing organization (“CDMO”) based in Hopkinton MA.

NOF and Phosphorex entered into a formal collaboration in April of 2024 with a focus on LNP (Lipid Nanoparticle) formulation development and manufacturing at the pre-clinical stage using NOF's proprietary LNP material, COATSOME® SS series. Phosphorex has extensive experience as a CDMO in LNP formulation development, process development and scale-up of manufacturing processes. NOF's investment will accelerate Phosphorex's introduction of GMP (Good Manufacturing Practice) manufacturing services at the clinical stage. In partnership with Phosphorex, NOF will offer a more advanced solution by seamlessly supporting our customers' LNP formulation development from initial feasibility to clinical applications.

NOF will create incremental value in the functional lipids business by developing and supplying test formulations to customers in a faster and more comprehensive manner than previously possible through the strengthened relationship with Phosphorex. Furthermore, this collaboration will strengthen NOF's position in the drug delivery market by translating the needs in LNP formulation development into material advancements of LNP components.

About COATSOME® SS Series

COATSOME® SS Series is our proprietary ionizable lipid that encapsulates nucleic acids such as mRNA, siRNA, and pDNA in lipid nanoparticles. The COATSOME® SS Series is highly degradable in vivo, enabling both efficient delivery of nucleic acids and low toxicity.

About Phosphorex



Established in 2005, Phosphorex is a CDMO specializing in nanoparticles. The company is well versed in the development of formulations using nanoparticle-based drug delivery technologies including LNP. Phosphorex is located in Hopkinton, Massachusetts, with easy access to Boston, where many pharmaceutical companies and bioventures have their research and development bases. The company supports pharmaceutical companies and bioventures through all stages of development, from early feasibility to clinical trials. For more information about Phosphorex, please visit www.phosphorex.com and follow us on [LinkedIn](#).

Contact

NOF CORPORATION

Corporate Communications Dept.

E-mail : info@nof.co.jp